Xbrane Biopharma
Xbrane Biopharma: FDA Resubmission in 2022 (Redeye)

2022-07-04 14:16
Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends to file a resubmission of its BLA for Xlucane during 2022.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Xbrane Biopharma - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -